Synthomer H1 EBITDA grows 5.4% despite revenue dip, as margin expansion and cost discipline drive strategic transformation amid market turbulence.
This article covers information on Synthomer PLC.
LON:SYNTSynthomer’s H1 2025 results reveal a business navigating stormy seas with impressive seamanship. While revenue dipped 9.8% to £925.2m amid global trade turbulence, the specialty chemicals firm squeezed out a 5.4% constant currency EBITDA increase to £77.8m. CEO Michael Willome’s “self-help” strategy-cost discipline and portfolio pruning-is proving its worth when macro winds turn foul.
Drill beneath the top-line decline and you’ll find robust margin expansion. Gross margins climbed 110bps versus H1 2024, extending a 400bps improvement over three years. How? Three key drivers:
This trifecta lifted group EBITDA margin to 8.4% (from 7.3%) despite volumes sinking 7.1%. The standout? Adhesive Solutions-EBITDA surged 64.8% to £35.4m as their performance turnaround hit stride.
AS isn’t just weathering the storm-it’s thriving. Margins exploded to 11.9% (from 7.1%) on £5m operational improvements. Their secret? Fixing the “end-to-end chain” from suppliers to logistics. The Henkel partnership for low-carbon adhesives exemplifies their innovation edge.
EBITDA jumped 21.5% to £16.6m, but beneath the surface: medical glove demand slumped 15.5% as customers burned through pre-tariff stockpiles. Offsetting this? Higher-margin reusable gloves and income from their US tech partnership. Clever portfolio tilting.
EBITDA sank 34.2% to £34.5m. Why? Energy solutions got clobbered by reduced oil/gas drilling. Silver lining? European construction showed green shoots. With new cost cuts accelerating, expect H2 improvement.
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
86 viewsLikes
No ratings yet
Occasional emails on automation, AI and finance. Unsubscribe any time.
Willome’s transformation hits milestones:
The playbook is clear: fewer commodities, more IP-protected specialties.
Net debt rose to £638.3m (H1 2024: £560.6m), but context matters:
Free cash flow should turn positive in H2, with capex tapering and working capital releases. Deleveraging remains priority #1.
Management guides to:
The medium-term ambition? Doubling earnings. Betting against Willome’s margin-maximizing, portfolio-optimizing machine looks unwise-even in tariff-riddled markets.
Synthomer won’t dazzle you with top-line fireworks. But in a sector where others drown in commodity quicksand, their specialty focus and cost discipline build lifeboats. The 110bps margin expansion amid demand chaos tells you everything. As trade winds keep gusting, this ship’s trimmed for turbulence.
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.